Pharmacokinetic characterization of favipiravir in patients with COVID‐19
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetic characterization of favipiravir in patients with COVID‐19
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-01-11
DOI
10.1111/bcp.15227
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract
- (2021) Tim Flerlage et al. NATURE REVIEWS MICROBIOLOGY
- Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
- (2021) Jean-Sélim Driouich et al. Nature Communications
- THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets
- (2021) Stephen PH Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2
- (2021) Henry Pertinez et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials
- (2021) Soheil Hassanipour et al. Scientific Reports
- Population pharmacokinetics of favipiravir in patients with COVID‐19
- (2021) Kei Irie et al. CPT-Pharmacometrics & Systems Pharmacology
- Augmented renal clearance in critically ill COVID-19 patients: Forewarned is forearmed
- (2021) Sofie Dhaese et al. JOURNAL OF CRITICAL CARE
- Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score
- (2020) Dong Ji et al. CLINICAL INFECTIOUS DISEASES
- Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2
- (2020) Philippine Eloy et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
- (2020) Yin‐Xiao Du et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID‐19
- (2020) Kei Irie et al. CTS-Clinical and Translational Science
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
- (2020) Hasan K. Siddiqi et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID‐19 (SARS‐COV‐2) treatments
- (2020) Emma H. Baker et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
- (2020) Nicolas Venisse et al. ANTIVIRAL RESEARCH
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
- (2017) Yousuke FURUTA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
- (2017) Thi Huyen Tram Nguyen et al. PLoS Neglected Tropical Diseases
- Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses
- (2016) Vincent Madelain et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now